Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 25 citing articles:

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S. Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 3, pp. 517-527
Open Access | Times Cited: 116
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Omid Hamid, Karl D. Lewis, Amy Weise, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 24, pp. 2928-2938
Open Access | Times Cited: 19
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
Stefano Marletta, Nicola Fusco, Enrico Munari, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 7, pp. 1073-1073
Open Access | Times Cited: 65
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Anna C. Pavlick, Charlotte E. Ariyan, Elizabeth I. Buchbinder, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e006947-e006947
Open Access | Times Cited: 23
Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis
Nina B. Curkovic, Kun Bai, Fei Ye, et al.
Cancers (2024) Vol. 16, Iss. 2, pp. 340-340
Open Access | Times Cited: 10
Current State of Adjuvant Therapy for Melanoma: Less Is More, or More Is Better?
Christopher D. Lao, Nikhil I. Khushalani, Christina V. Angeles, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 738-744
Open Access | Times Cited: 25
Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
Gen Lin, Zhijie Wang, Qian Chu, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 5, pp. 419-426
Open Access | Times Cited: 5
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma
Rikke Boedker Holmstroem, Sidsel Pedersen, Rebecca Jurlander, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114023-114023
Open Access | Times Cited: 5
Adjuvant therapy for stage II melanoma: the need for further studies
Rebecca Lee, Mario Mandalà, Georgina V. Long, et al.
European Journal of Cancer (2023) Vol. 189, pp. 112914-112914
Open Access | Times Cited: 12
Melanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment
Michael J. Diaz, Isabella Mark, Daphnee Rodriguez, et al.
Life (2023) Vol. 13, Iss. 3, pp. 828-828
Open Access | Times Cited: 11
Optimal systemic therapy for high-risk resectable melanoma
Alexander M.M. Eggermont, Omid Hamid, Georgina V. Long, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 7, pp. 431-439
Closed Access | Times Cited: 18
Melanoma—Modern Treatment for Metastatic Melanoma
Maya Dimitrova, Jeffrey S. Weber
The Cancer Journal (2024) Vol. 30, Iss. 2, pp. 79-83
Closed Access | Times Cited: 3
Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study
Michael Weichenthal, Eva Ellebæk, Joanna Mangana, et al.
European Journal of Cancer (2025) Vol. 220, pp. 115339-115339
Closed Access
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study
Jason J. Luke, Paolo A. Ascierto, Muhammad Adil Khattak, et al.
European Journal of Cancer (2025), pp. 115381-115381
Closed Access
Real‐world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions
Vincenzo De Falco, Gabriella Suarato, Rossella Napolitano, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 1, pp. 133-140
Open Access | Times Cited: 9
Transition of the PD‑1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re‑challenge
T Nose, Yohei Funakoshi, Hirotaka Suto, et al.
Molecular and Clinical Oncology (2022) Vol. 16, Iss. 5
Open Access | Times Cited: 8
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report
Maria D’Apolito, Rocco Spagnuolo, Maria Anna Siciliano, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13
Open Access | Times Cited: 6
Adverse events associated with postoperative outcomes of adjuvant anti‐PD‐1 antibody therapy in both acral and non‐acral cutaneous melanomas: A multicenter, observational, post hoc analysis study
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, et al.
The Journal of Dermatology (2023) Vol. 51, Iss. 3, pp. 458-462
Open Access | Times Cited: 2
Treatment of Recurrent Melanoma Following Adjuvant Therapy
Nausicaa Malissen, Jean‐Jacques Grob
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 3, pp. 333-341
Closed Access | Times Cited: 2
Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment
Michael Weichenthal, Inge Marie Svane, Johanna Mangana, et al.
EJC Skin Cancer (2024) Vol. 2, pp. 100271-100271
Closed Access
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?
Joseph Zouein, Nabih Naim, Hampig Raphaël Kourié
Immunotherapy (2023) Vol. 15, Iss. 2, pp. 93-100
Closed Access | Times Cited: 1
Pembrolizumab (Keytruda)
CADTH
Canadian Journal of Health Technologies (2023) Vol. 3, Iss. 2
Closed Access | Times Cited: 1
Combination Immune Checkpoint Inhibition: Is First Line Best?
Grant A. McArthur
Journal of Clinical Oncology (2023) Vol. 41, Iss. 15, pp. 2691-2694
Open Access
Melanoma treatment: what’s next?
Gabriella Emri, Beatrix Ványai, Lilla Soltész, et al.
Bőrgyógyászati és Venerológiai Szemle (2022) Vol. 98, Iss. 5, pp. 256-262
Open Access
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
Vincenzo De Falco, Stefania Napolitano, Luigi Pio Guerrera, et al.
Dermatology Practical & Conceptual (2021), pp. 2021165S-2021165S
Open Access
Page 1

Scroll to top